伯舒替尼一水合物，CAS 登记号 918639-08-4，由济南圣和化工有限公司现货供应，可提供纯度 按批次COA提供(不公开发布) 的规格，下游主要用于医药中间体及原料药。支持样品与小批量试用，批量价格请联系我们获取，验收以批次 COA 为准。
医药中间体及原料药
每批随货提供 COA；可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号，一个工作日内回复报价。
本页已列出 伯舒替尼一水合物 的 CAS 号：918639-08-4，可与随货 COA 核对。
常见纯度为 按批次COA提供(不公开发布)，包装形式为 按订单/批次确认(不公开发布)，特殊规格可在询价时说明。
主要涉及医药中间体及原料药。
来信 info@591daili.com 或 WhatsApp 联系，提供产品名称、CAS 号与数量，确认价格与交期后即可安排发货，验收以批次 COA 为准。
Bosutinib monohydrate · CAS 918639-08-4 · C26H31Cl2N5O4. UNII 844ZJE6I55.
| CAS Registry Number | 918639-08-4 |
|---|---|
| PubChem CID | 11990828 |
| Molecular formula | C26H31Cl2N5O4 |
| IUPAC name | 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;hydrate |
| UNII (FDA) | 844ZJE6I55 |
| Molecular Weight | 548.5 |
|---|---|
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | 547.1753099 |
| Monoisotopic Mass | 547.1753099 |
| Topological Polar Surface Area | 83.9 |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 734 |
| Reported hazard statements | H317 (100%), H400 (100%), H410 (100%) |
|---|
H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]
H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]
Bosutinib monohydrate; 918639-08-4; bosutinib hydrate; SKI-606 monohydrate; bosutinib.H2O; UNII-844ZJE6I55; Bosutinib (as monohydrate); 844ZJE6I55; CHEBI:68533; DTXSID20238722; RefChem:58902; DTXCID70161213; 380843-75-4 , anhydride; Bosutinib (hydrate); Bosutinib hydrate (JAN); BOSUTINIB HYDRATE [JAN]
CAS 918639-08-4; molecular formula C26H31Cl2N5O4; molecular weight — g/mol.
Bosutinib monohydrate, 918639-08-4, bosutinib hydrate, SKI-606 monohydrate, bosutinib.H2O, UNII-844ZJE6I55.
Hazard statements reported: H317, H400, H410.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.